Cystatin C and cardiovascular risk;Cystatine C et risque cardiovasculaire

Annales de Biologie Clinique

Volumn 68, Issue 5, 2010, Pages 517-529

  Taglieri, Nevio ^a   Koenig, Wolfgang ^b   Kaski, Juan Carlos ^a  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^b UNIVERSITY HOSPITAL ULM   (Germany)

Author keywords

Cardiovascular disease; Cystatin C; Renal function

Indexed keywords

CREATININE; CYSTATIN C;

BLOOD; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY FAILURE; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY DISEASE; MALE; MIDDLE AGED; PATHOPHYSIOLOGY; PREDICTION AND FORECASTING; REVIEW; RISK FACTOR;

CARDIOVASCULAR DISEASES; CREATININE; CYSTATIN C; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; KIDNEY DISEASES; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; RENAL INSUFFICIENCY, CHRONIC; RISK FACTORS;

EID: 77958491998     PISSN: 00033898     EISSN: 19506112     Source Type: Journal    
DOI: 10.1684/abc.2010.0466     Document Type: Article

References (61)

1. Coresh J, Selvin E, Stevens LA, Manzi J, Kusek JW, Eggers P, et al. Prevalence of chronic kidney disease in the United States. JAMA 2007 ; 298 : 2038-47. (Pubitemid 350074801)
2. K/DOQI clinical practice guidelines for chronic kidney disease : evaluation, classification, and stratification. Am J Kidney Dis 2002 ; 39 : S1-6.
3. Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm. LL, et al. Kidney disease as a risk factor for development of cardiovascular disease : a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention, Circulation 2003 ; 108 : 2154-69.
4. Go AS, Chertow GM, Fan D, MeCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004 ; 351 : 1296-305.
5. Anavekar NS, McMurray JJ, Velazquez EJ, Solomon SD, Kober L, Rouleau JL, et al Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med 2004 ; 351 : 1285-95.
6. Nlnomiya T, Kiyohara Y, Tokuda Y, Doi Y, Arima H, Harada A, et al Impact of kidney disease and blood pressure on the development of cardiovascular disease : an overview from the Japan Arteriosclerosis Longitudinal Study. Circulation 2008 ; 118 : 2694-701.
7. Hsu CY, Chertow GM, Curhan GC. Methodological issues in studying the epidemiology of mild to moderate chronic renal insufficiency. Kidney Int '2002 ; 61 : 1567-76.
8. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976 ; 16 : 31-41.
9. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine : a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999 ; 130 : 461-70.
10. Gonwa TA, Jennings L, Mai ML, Stark PC, Levey AS, Klintmalm GB. Estimation of glomerular filtration rates before and after orthotopic liver transplantation : evaluation of current equations. Liver Transpl 2004;10:301-9. (Pubitemid 38240131)
11. Lamb EJ, Webb MC, Simpson DE, Coakley AJ, Newman DJ, O'Riordan SE. Estimation of glomerular filtration rate in older patients with chronic renal insufficiency : is the modification, of diet in renal disease formula an improvement ? JAm Geriatr Soc 2003 ; 51 : 1012-7.
12. Poggio ED, Wang X, Greene T, Van LF, Hall PM. Performance of the modification of diet in renal disease and Cockcroft-Gault equations in the estimation of GFR in health and in chronic kidney disease. J Am Soc Nephrol 2005 ; 16:459-66. (Pubitemid 41725142)
13. Dhamidharka VR, Kwon C, Stevens G. Serum cystatin C is superior to serum creatinine as a marker of kidney function : a meta-analysis. Am J Kidney Dis 2002 ; 40 : 221-6. (Pubitemid 34827638)
14. Grubb A, Nyman U, Bjork J, Lindstrom V, Rippe B, Sterner G, et al. Simple cystatin C-based prediction equations for glomerular filtration rate compared with the modification of diet in renal disease prediction equation for adults and the Schwartz and the Counahan-Barratt prediction equations for children. Clin Chem 2005 ; 51 : 1420-31. (Pubitemid 41060874)
15. Grubb A, Bjork J, Lindstrom V, Sterner G, Bondesson P, Nyman U. A cystatin C-based formula without anthropometric variables estimates glomerular filtration rate better than, creatinine clearance using the Cockcroft-Gault formula. Scand J Clin Lab Invest 2005 ; 65 : 153-62. (Pubitemid 40571151)
16. Abrahamson M, Dalboge H, Olafsson I, Carlsen S, Grubb A. Efficient production of native, biologically active human cystatin C by Escherichia coli. FEBS Lett 1988 ; 236 : 14-8.
17. Knight EL, Verhave JC, Spiegelman D, Hillege HL, de ZD, Curhan GC, et al. Factors influencing serum cystatin C levels other than renal function and the impact on renal function measurement. Kidney Int 2004; 65: 1416-21. (Pubitemid 38406982)
18. Stevens LA, Schmid CH, Greene T, Li L, Beck GJ, Joffe MM, et al. Factors other than glomerular filtration rate affect serum, cystatin C levels. Kidney Int 2009 ; 75 : 652-60.
19. Macdonald J, Marcora S, Jibani M, Roberts G, Kumwenda M, Glover R, et al. GFR estimation using cystatin C is not independent of body composition, Am J Kidney Dis 2006 ; 48 : 712-9. (Pubitemid 44740040)
20. Stevens LA, Coresh J, Schmid CH, Feldman HI, Froissart M, Kusek J, et al. Estimating GFR using serum cystatin C alone and in combination with, serum creatinine : a pooled analysis of 3,418 individuals with CKD. Am J Kidney Dis 2008 ; 51 : 395-406. (Pubitemid 351273480)
21. Vupputuri S, Fox CS, Coresh J, Woodward M, Muntner P. Differential estimation of CKD using creatinine-versus cystatin C-based estimating equations by category of body mass index. Am J Kidney Dis 2009 ; 53 : 993-1001.
22. Roos JF, Doust J, Tett SE, Kirkpatrick CM. Diagnostic accuracy of cystatin C compared to serum, creatinine for the estimation of renal dysfunction in adults and children : a meta-analysis. Clin Biochem 2007;40:383-91. (Pubitemid 46303950)
23. Parikh NI, Hwang SJ, Yang Q, Larson MG, Guo CY, Robins SJ, et al Clinical correlates and heritability of cystatin C (from the Framingham Offspring Study). Am J Cardiol 2008 ; 102 : 1194-8.
24. Kannel WB, Feinleib M, McNamara PM, Garrison RJ, Castelli WP. An investigation of coronary heart disease in families : the Framingham offspring study. Am J Epidemiol 1979 ; 110 : 281-90. (Pubitemid 10204328)
25. Muntner P, Mann D, Winston J, Bansilal S, Farkouh ME. Serum cystatin C and increased coronary heart disease prevalence in US adults without chronic kidney disease. Am J Cardiol 2008 ; 102 : 54-7.
26. BiId DE, Bluemke DA, Burke GL, Detrano R, ez Roux AV, Folsom AR, et al. Multi-ethnic study of atherosclerosis : objectives and design. Am J Epidemiol 2002 ; 156 : 871-81.
27. Kestenbaum B, Rudser KD, de B I, Peralta CA, Fried LF, Shlipak MG, et al Differences in kidney function and incident hypertension : the multi-ethnic study of atherosclerosis. Ann Intern Med 2008 ; 148 : 501-8. (Pubitemid 351665418)
28. Fried LP, Borhani NO, Enright P, Furberg CD, Gardin JM, Kronmal RA, et al The Cardiovascular Health Study : design and rationale. Ann Epidemiol 1991 ; 1 : 263-76.
29. Shlipak MO, Sarnk MJ, Katz R, Fried LF, Seliger SL, Newman AB, et al, Cyitatin C end the risk of death and cardiovaieular events among elderly persons, N Engl J Med 2003 ; 332: 2049-60
30. Samak MJ, Katz R, Stehman-Breen CO, Fried LF, Jenny NS, Peaty BM, et al. Cystatin C concentration a risk factor for heart failure in older adults, Ann Intern Med 2005 ; 142 : 497-505. (Pubitemid 40490915)
31. Shlipak MG, Katz R, Fried LF, Jenny NS, Stehman-Breen CO, Newman AB, et al., Cyitatin-C and mortality in elderly persons with heart failure, J Am Coll Cardiol 2005 ; 45 : 268-71. (Pubitemid 40094736)
32. O'Hare AM, Newman AB, Katz R, Fried LF, Stehman-Breen CO, Seliger SL, et al. Cystatin C and incident peripheral arterial disease events in the elderly : results from the Cardiovascular Health Study, Arch Intern Med 2005; 165 : 2666-70. (Pubitemid 41785066)
33. Shlipak MG, Katz R, Samak MJ, Fried LF, Newman AB, StehmanBreen C, et al. Cystatin C and prognosis for cardiovascular and kidney outcomes in elderly persons without chronic kidney disease, Ann Intern Med 2006; 145 : 237-46 (Pubitemid 46768607)
34. Ix JH, Shlipak MO, Chertow OM, Whooley MA. Association of cystatin C with mortality, cardiovascular events, and incident heart failure among persons with coronary heart disease data from the Heart and Soul Study, Circulation 2007; 115: 173-9.
35. Ix JH, Shlipak MO, Liu HH, Schiller NB, Whooley MA. Association between renal insufficiency and inducible ischemia in patients with coronary artery disease : the heart and soul study. J Am Soc Nephrol 2003 ; 14 : 3233-8.
36. Koenig W, Twardelia D, Brenner H, Rothenbaeher O, Plasma concentrations of cystatin C in patients with coronary heart disease and risk for secondary oardiovasoular events : more than simply a marker of glomerular filtration rate, Clin Chem 2005 ; 51 : 321-7. (Pubitemid 40175801)
37. Jemberg T, Lindahl B, James S, Larsson A, Hansson LO, Wallentin L. Cystatin C : a novel predictor of outcome in suspected or confirmed nonST-elevation acute coronary syndrome, Circulation 2004 ; 110: 2342-8. (Pubitemid 39407337)
38. Windhausen F, Hirsch A, Fischer J, van der Zee PM, Sanders GT, van Straalen JP, et al. Cystatin C for enhancement of risk stratification in non-ST elevation acute coronary syndrome patients with an increased troponin T. Clin Chem 2009; 55: 1118-25.
39. Keller T, Messow CM, Lubos E, Nicaud V, Wild PS, Rupprecht HJ, et al. Cystatin C and cardiovascular mortality in patients with coronary artery disease and normal or mildly reduced kidney function : results from the AtheroOene study. Eur Heart J 2009 ; 30: 314-20.
40. Blankanberg S, Rupprecht HJ, Bickel C, Torzewski M. Hafner O, Tiret L, et al. Glutathione peroxidase 1 activity and cardiovaieular events in patients with coronary artery disease N Engl J Med 2003; 349: 1605-13. (Pubitemid 37288568)
41. Menon V, Shlipak MO, Wang X, Coresh J, Oreene T, Stevens L, et al. Cystatin C as a risk factor for outcomes in chronic kidney disease. Ann Intern Med 2007 ; 147 :19-27. (Pubitemid 351664630)
42. Zethelius B, Berglund L, Sundstrom J, Ingelsson E, Basu S, Larsson A, et al. Use of multiple biomarkers to iImprove the prediction of death from cardiovascular causes. N Engl J Med 2008 ; 358 : 2107-16. (Pubitemid 351679597)
43. Shlipak MG, Katz R, Cushman M, Samak MJ, Stehman-Breen C, Psaty BM, et al. Cystatin-C and inflammatory markers in the ambulatory elderly, Am J Med 2005; 118: 1416.e25-1416.e31. (Pubitemid 41832346)
44. Muntner P, Hamm LL, Kusek JW, Chen J, Whelton PK, He J. The prevalence of nontraditional risk factors for coronary heart disease in patients with chronic kidney disease, Ann Intern Med 2004 ; 140:9-17. (Pubitemid 38055916)
45. Singh D, Whooley MA, Ix JH, Ali S, Shlipak MO. Association of cystatin C and eitimated GFR with inflammatory biomarkers : the Heart and Soul Study. Nephrol Dial Transplant 2007 ; 22: 1087-92. (Pubitemid 46523422)
46. Keller C, Katz R, Cushman M, Fried LF, Shlipak M, Association of kidney function with inflammatory and procoagulant marken in a diverse cohort : a cross-sectional analysis from the Multi-Ethnic Study of Atherosclerosis (MBSA), BMC Niphrol 2008; 9:9.
47. Leung-Tack J, Tavera C, Gensac MC, Martinez J, Colle A, Modulation of phagocytosis-associated respiratory burst by human cystatin C : role of the N-terminal tetrapeptide Lys-Pro-Pro-Arg. Exp Cell Res 1990 ; 188:16-22. (Pubitemid 20147848)
48. Sukhova GK, Shi GP, Simon DI, Chapman HA, Libby P, Expression of the elastolytic cathepsins S and K in human atheroma and regulation of their production in smooth muscle cells, J Clin Invest 1998 ; 102 : 576-83. (Pubitemid 28376160)
49. Liu J, Sukhova GK, Sun JS, Xu WH, Libby P, Shi QP, Lysosomal cysteine proteases in atherosclerosis, Arterioseler Thromb Vasc Biol 2004 ; 24: 1359-66.
50. Shi GP, Sukhova GK, Grubb A, Ducharme A, Rhode LH, Lee RT, et al. Cystatin C deficiency in human atherosclerosis and aortic aneurysms, J Clin Invest 1999; 104: 1191-7. (Pubitemid 29536290)
51. Bengtsson E, To F, Hakansson K, Grubb A, Branen L, Nilsson J, et al. Lack of the cysteine protease inhibitor cystatin C promotes atherosclerosis in apolipoprotein E-deficient mice, Arterioseler Thromb Vasc Biol 2005; 25: 2151-6. (Pubitemid 41416314)
52. Oorni K, Sneck M, Bromme D, Pentikainen MO, Lindstedt KA, Mayranpaa M, et al. Cysteine protease cathepsin F is expressed in human atherosclerotic lesions, is secreted by cultured macrophages, and modifies low density lipoprotein particles in vitro. J Biol Chem 2004 ; 279: 34776-84. (Pubitemid 39318110)
53. Lutgens E, Lutgens SP, Faber BC, Heeneman S, Gijbels MM, de Winther MP, et al. Disruption of the cathepsin K gene reduces atherosclerosis progression and induces plaque fibrosis but accelerates macrophage foam cell formation. Circulation 2006 ; 113: 98-107.
54. Rodgers KJ, Watkins DJ, Miller AL, Chan PY, Karanam S, Brissette WH, et al. Destabilizing role of cathepsin S in murine atherosclerotic plaques. Artirioscler Thromb Vasc Biol 2006; 26: 851-6. (Pubitemid 43732162)
55. Eriksson P, Deguchi H, Samnegard A, Lundman P, Boquist S, Tornvall P, et al. Human evidence that the cystatin C gene is implicated in focal progression of coronary artery disease, Artirioseler Thromb Vasc Biol 2004; 24: 551-7. (Pubitemid 38326152)
56. Loew M, Hoffmann MM, Koenig W, Brenner H, Rothenbaeher D. Genotype and plasma concentration of cystatin C in patients with coronary heart disease and risk for secondary cardiovascular events, Arterioscler Thromb Vasc Biol 2005 ; 25 : 1470-4. (Pubitemid 40923370)
57. Manetti L, Pardini B, Genovesi M, Campomori A, Orasso L, Mbrselli LL, et al. Thyroid function differently affects serum cystatin C and creatinine concentrations. J Endocrinol Invest 2005; 28: 346-9. (Pubitemid 43162754)
58. Risch L, Herklotz R, Blumberg A, Huber AR, Effects of glucocorticoid immunosuppression on serum cystatin C concentrations in renal transplant patients. Clin Chem 2001;47: 2055-9. (Pubitemid 33010731)
59. Maurer MS, Burkhoff D, Fried LP, Gottdiener J, King DL, Kitzman DW, Ventricular structure and function in hypertensive participants with heart failure and a normal ejection fraction : the Cardiovascular Health Study, J Am Coll Cardiol 2007; 49: 972-81. (Pubitemid 46320198)
60. Lassus J, Harjola VP, Sund R, Siirila-Waris K, Melin J, Peuhkurinen K, et al. Prognostic value of cystatin C in acute heart failure in relation to other markers of renal function and NT-proBNP. Eur Heart J 2007; 28:1841-7. (Pubitemid 47236639)
61. Naruse H, Ishii J, Kawai T, Hattori K, Ishikawa M, Okumura M, et al. Cystatin C in acute heart failure without advanoed renal impairment. Am J Med 2009 ; 122: 566-73.